Blow to Modi govt as Interpol gives clean chit to Dr Zakir Naik, cancels red corner notice

Belgaum, Feb 24: Around 20 people entered a boys' hostel premises in Karnataka's Belgaum with rods and bats and destroyed properties allegedly over ragging of a girl by two hostel residents.

The incident took place on February 23 and was captured in the CCTV camera.

According to Belgaum Police, a gang of 20 people entered Dr BR Ambedkar post metric hostel premises in Belgaum with rods and bats. The group destroyed the properties of hostel, bikes, and scooters.

Police said this is an issue of ragging and during the incident, no students were injured.

Further, the investigation is underway.

Mangaluru/Udupi, May 28: Coastal Karnataka witnessed further spike in covid-19 cases today with 27 people testing positive for coronavirus in Udupi and six in Dakshina Kannada. 

Among 27 coronavirus patients in Udupi 18 are males and 9 females. Among them 24 have come from Maharashtra, two from Telangana and one from Kerala. All of them were under quarantine.

As many as 147 confirmed cases of coronavirus have been reported so far in the district, including a death. Three have recovered, and 143 are active.

In Dakshina Kannada, 2 females aged 18 and 62, and four males aged 25, 36, 50 and 61, are the ones to be tested positive. All the six persons to test positive are Maharashtra returnees.

With this, the number of cases in DK has increased to 87, out of which 51 are currently active. As many as 29 persons have recovered and been discharged, and seven deaths have occurred so far.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.